January 25th 2023
1 out 3 Medicaid patients who might have benefited from targeted therapy —mainly Tagrisso and Alecensa — for metastatic lung cancer did not receive it, according to estimates by a trio Harvard-affiliated researchers.
September 14th 2021
Best Practices to Define, Care for Lung CancerJuly 19th 2021
When wondering what step to take first after learning of your cancer diagnosis, assembling the right care team and creating a treatment plan designed uniquely is important to get you on the right track. Comprehensive biomarker testing can then help identify your type of lung cancer and help move steps forward for proper care.
DFCI's Jacob Sands Discusses All Things Considered About Lung Cancer ScreeningJuly 6th 2021
Sands ,a medical oncologist who specializes in lung cancer, says the false discovery has been misconstruted as a false positive rate. He also makes a case for early detection and new USPSTF as working to correct disparities.
ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks PromisingJune 4th 2021
The FDA approved Amgen’s Lumakras (sotorasib) last week, the first drug targeting KRAS-mutated cancer to get the agency’s OK. But the clinical and commercial future of the drug is uncertain.
Black Lung Cancer Patients May Be Missing Out On Era of Targeted TherapyJune 1st 2021
Meta-analysis shows lower prevalence of four known driver mutations among Black lung cancer patients. More research into tumor biology of Black patients might yield targeted therapies that would benefit Black lung cancer patients, says the lead author, Philippos A. Costa, M.D.
Atezolizumab Extends Disease-Free Survival in Patients with PD-L1 Positive Early NSCLCJune 1st 2021
Patients who were PD-L1 positive with early stage non-small-cell lung cancer had better results and a lower risk of death or progression compared to a cohort on best supportive care.
Lung Cancer Screening Has Had Few Takers. Will Updated Recommendations Make a Difference?May 20th 2021
A small fraction of those who were eligible under previous U.S. Preventive Services Task Force recommendations were screened with low-dose CT scans. New recommendations will make an additional 6.4 million Americans eligible, but a number of barriers to screening remain.
How the Menthol Cigarette Ban May Affect the African American Smoking ParadoxMay 5th 2021
The prevalence of smoking among African American young adults “catches up” with other groups despite the low rate among Black youth. The ban on menthol may affect this and other aspects of smoking patterns among Black Americans.
KRAS Mutation Could Guide Treatment Decisions in Nonsmall Cell Lung CancerMay 4th 2021
Chemo in combination with immunotherapy was preferable to immunotherapy alone in patients with a mutation of the KRAS gene and high levels of programmed cell death ligand 1, according to findings reported in JAMA Oncology.
New Lung Cancer Screening Recommendations Can Reach More Patients But Won't Remove All BarriersMarch 11th 2021
The U.S. Preventative Services Task Force recently released an updated recommendation addressing lung cancer screening criteria at a sooner rate starting at 50-years-old rather than 55. The task force says this expansion will be especially helpful to those who face disparities to screening. Although, it won’t cover all disparities.
Similar Cancer Risk Between Patients With MS, General Population in the UK, Study FindsOctober 23rd 2020
Study found that while frequency of cancer among people with multiple sclerosis (MS) increased over time, the overall cancer risk is similar between patients with MS and the general population.
AstraZeneca's Adrian Kilcoyne Sees Paradigm Shift in Lung Cancer TreatmentJune 2nd 2020
Adrian Kilcoyne MD MBA MPH, vice president, US Medical Affairs and HEOR, oncology, AstraZeneca, discusses a paradigm shift in lung cancer treatment due to the overwhelming efficacy of the EGFR-TKI treatment.